BioCentury
BioCentury
ARTICLE | Regulation

Pricing the uncertainty in expedited therapies

How new ideas about pay for performance aim to temper uncertainties, and controversies, about accelerated approvals

By Steve Usdin, Washington Editor
September 2, 2021 1:04 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Biogen Inc.

Sarepta Therapeutics Inc.

Duke University

Massachusetts Institute of Technology

BCIQ Company Profiles

Biogen Inc.

Sarepta Therapeutics Inc.

Duke University

Massachusetts Institute of Technology

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS